Anticancer activities of sulindac in prostate cancer cells associated with c‑Jun NH2‑terminal kinase 1/β‑catenin signaling

Du,Jun; Guo,Yongchen; Bao,Yonghua; Xing,Mengtao; Mahmoud,Abeer M.; Che,Zhenyong; Chen,Zhiguo; Yang,Wancai

doi:10.3892/ol.2014.2084

Anticancer activities of sulindac in prostate cancer cells associated with c‑Jun NH2‑terminal kinase 1/β‑catenin signaling

Authors:
- Jun Du
- Yongchen Guo
- Yonghua Bao
- Mengtao Xing
- Abeer M. Mahmoud
- Zhenyong Che
- Zhiguo Chen
- Wancai Yang
View Affiliations

Affiliations: Department of Urology, Xinxiang Central Hospital, The Teaching Hospital of Xinxiang Medical University, Xinxiang, Henan 453000, P.R. China, Department of Laboratory Medicine, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China, Department of Microbiology, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China, Department of Pathology, University of Illinois at Chicago, Chicago, IL 60612, USA, Department of Neurology, Xinxiang Central Hospital, The Teaching Hospital of Xinxiang Medical University, Xinxiang, Henan 453000, P.R. China, Department of Pathology, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China
Published online on: April 25, 2014 https://doi.org/10.3892/ol.2014.2084
Pages: 313-316

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The non‑steroidal anti‑inflammatory agent, sulindac, has shown strong effects on cancer prevention in colorectal cancers, however, its anticancer activities on prostate cancer remain unclear. In the current study, human prostate cancer cell lines, LNCaP and PC‑3, were treated with various concentrations of sulindac and it was found that sulindac significantly inhibits prostate cancer cell proliferation and promotes cell apoptosis in a dose‑ and time‑dependent manner. Further studies revealed that sulindac significantly induces c‑Jun NH2‑terminal kinase (JNK) 1 phosphorylation and inhibits β‑catenin at the transcriptional and post‑transcriptional levels. In conclusion, by targeting the JNK1/β‑catenin signaling pathway, sulindac may present a potential preventive or therapeutic agent for treatment of patients with prostate cancer.

View Figures

View References

1	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011.
2	Clevers H: Colon cancer - understanding how NSAIDs work. N Engl J Med. 354:761–763. 2006.
3	Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, et al; AACR Task Force on Cancer Prevention. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin Cancer Res. 12:3661–3697. 2006.
4	Yang W, Bancroft L and Augenlicht LH: Methylation in the p21WAF1/cip1 promoter of Apc+/−, p21+/− mice and lack of response to sulindac. Oncogene. 24:2104–2109. 2005.
5	Yang W, Bancroft L, Liang J, Zhuang M and Augenlicht LH: p27kip1 in intestinal tumorigenesis and chemoprevention in the mouse. Cancer Res. 65:9363–9368. 2005.
6	Han A, Song Z, Tong C, Hu D, Bi X, Augenlicht LH and Yang W: Sulindac suppresses β-catenin expression in human cancer cells. Eur J Pharmacol. 583:26–31. 2008.
7	Song Z, Tong C, Liang J, Dockendorff A, Huang C, Augenlicht LH and Yang W: JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo. Eur J Pharmacol. 560:95–100. 2007.
8	Bi X, Pohl N, Dong H and Yang W: Selenium and sulindac are synergistic to inhibit intestinal tumorigenesis in Apc/p21 mice. J Hematol Oncol. 6:82013.
9	Chang L and Karin M: Mammalian MAP kinase signalling cascades. Nature. 410:37–40. 2001.
10	Bode AM and Dong Z: The functional contrariety of JNK. Mol Carcinog. 46:591–598. 2007.
11	Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell. 103:239–252. 2000.
12	Weston CR and Davis RJ: The JNK signal transduction pathway. Curr Opin Cell Biol. 19:142–149. 2007.
13	Weston CR, Lambright DG and Davis RJ: Signal transduction. MAP kinase signaling specificity. Science. 296:2345–2347. 2002.
14	Tong C, Yin Z, Song Z, Dockendorff A, Huang C, Mariadason J, Flavell RA, Davis RJ, Augenlicht LH and Yang W: c-Jun NH2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression. Am J Pathol. 171:297–303. 2007.
15	Bode AM and Dong Z: Signal transduction pathways in cancer development and as targets for cancer prevention. Prog Nucleic Acid Res Mol Biol. 79:237–297. 2005.
16	Liu J and Lin A: Role of JNK activation in apoptosis: a double-edged sword. Cell Res. 15:36–42. 2005.
17	Dong C, Yang DD, Wysk M, Whitmarsh AJ, Davis RJ and Flavell RA: Defective T cell differentiation in the absence of Jnk1. Science. 282:2092–2095. 1998.
18	Kuan CY, Yang DD, Samanta Roy DR, Davis RJ, Rakic P and Flavell RA: The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron. 22:667–676. 1999.
19	Liu J, Minemoto Y and Lin A: c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor alpha-induced c-Jun kinase activation and apoptosis. Mol Cell Biol. 24:10844–10856. 2004.
20	Hu D, Bi X, Fang W, Han A and Yang W: GSK3beta is involved in JNK2-mediated beta-catenin inhibition. PLoS One. 4:e66402009.
21	Hu D, Fang W, Han A, Gallagher L, Davis RJ, Xiong B and Yang W: c-Jun N-terminal kinase 1 interacts with and negatively regulates Wnt/beta-catenin signaling through GSK3beta pathway. Carcinogenesis. 29:2317–2324. 2008.